Assessment of cellular proliferation in tumors by PET using 18F-ISO-1

Journal of Nuclear Medicine

Volumn 54, Issue 3, 2013, Pages 350-357

  Dehdashti, Farrokh ^a,b   Laforest, Richard ^a,b   Gao, Feng ^b,c   Shoghi, Kooresh I ^a,b   Aft, Rebecca L ^b,c   Nussenbaum, Brian ^b,c   Kreisel, Friederike H ^b,c   Bartlett, Nancy L ^b,c   Cashen, Amanda ^b,c   Wagner Johnson, Nina ^b,c   MacH, Robert H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F ISO 1; Cancer; Cell proliferation; PET

Indexed keywords

KI 67 ANTIGEN; N [4 (6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL)BUTYL] 2 (2 FLUOROETHOXY) 5 METHYLBENZAMIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GALLBLADDER; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LYMPHOMA; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; TUMOR GROWTH; WHOLE BODY PET;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; FLUORINE RADIOISOTOPES; HEAD AND NECK NEOPLASMS; HUMANS; KI-67 ANTIGEN; LYMPHOMA; MALE; MIDDLE AGED; MITOTIC INDEX; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOPHARMACEUTICALS;

EID: 84874882616     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111948     Document Type: Article

References (30)

1. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 2006;8:216.
2. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7:834-846. (Pubitemid 350006258)
3. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
4. Mier W, Haberkorn U, Eisenhut M. [18F]FLT; portrait of a proliferation marker. Eur J Nucl Med Mol Imaging. 2002;29:165-169. (Pubitemid 34143447)
5. 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med. 2003;44:1432-1434. (Pubitemid 39663356)
6. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400-419. (Pubitemid 47505221)
7. Mach RH, Dehdashti F, Wheeler KT. PET radiotracers for imaging the proliferative status of solid tumors. PET Clin. 2009;4:1-15.
8. Tu Z, Xu J, Jones LA, et al. Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. J Med Chem. 2007;50:3194-3204. (Pubitemid 47065968)
9. Lehr HA, Hansen DA, Kussick S, et al. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol. 1999;30:1314-1320. (Pubitemid 29534293)
10. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]- (2)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747. (Pubitemid 20260955)
11. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840. (Pubitemid 26292051)
12. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322. (Pubitemid 30054364)
13. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut. 2003;52: 1602-1606. (Pubitemid 37363445)
14. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008;49(suppl 2):64S-80S. (Pubitemid 351948037)
15. 18F-39-fluoro-39-deoxy- L-thymidine. Clin Cancer Res. 2004;10:1685-1690. (Pubitemid 38435559)
16. 18F-FLT and 18FFDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610-1616. (Pubitemid 47476919)
17. 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393-401. (Pubitemid 43289860)
18. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 39deoxy-39-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315-3323. (Pubitemid 35340704)
19. 18F-FLT PET studies in lung tumors. J Nucl Med. 2011;52:1181-1188.
20. 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2009;36:382-388.
21. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027-2032. (Pubitemid 40022149)
22. 18F-FLT in cancer imaging: does it really reflect proliferation? Eur J Nucl Med Mol Imaging. 2008;35: 523-526.
23. 123I-iodo-4- methoxybenzamide of patients with suspected primary breast cancer: first clinical results. J Nucl Med. 2002;43:1647-1649. (Pubitemid 35424989)
24. 11-CSA4503: a feasibility study. J Nucl Med. 2004;45:1939-1945. (Pubitemid 47618454)
25. Mach RH, Huang Y, Buchheimer N, et al. [[18F]N-(49-fluorobenzyl)-4-(3- bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [18F]FDG, and [125I]IUDR. Nucl Med Biol. 2001;28:451-458. (Pubitemid 32521004)
26. Bem WT, Thomas GE, Mamone JY, et al. Overexpression of sigma receptors in nonneural human tumors. Cancer Res. 1991;51:6558-6562.
27. Vilner BJ, Bowen WD. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur J Pharmacol. 1993;244:199-201. (Pubitemid 23028292)
28. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55: 408-413.
29. Aydar E, Palmer CP, Djamgoz MB. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res. 2004;64:5029-5035. (Pubitemid 39006512)
30. Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 1997;57:156-161. (Pubitemid 27020346)